<DOC>
	<DOCNO>NCT00809211</DOCNO>
	<brief_summary>RATIONALE : Nilotinib may stop growth cancer cell block enzymes need cell growth . PURPOSE : This phase II trial study well nilotinib work treat patient newly diagnose chronic phase chronic myelogenous leukemia .</brief_summary>
	<brief_title>Nilotinib Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - To establish complete cytogenetic response rate 6 month patient newly diagnose Philadelphia chromosome-positive chronic phase chronic myelogenous leukemia treat nilotinib . Secondary - To establish complete cytogenetic response rate 3 , 9 , 12 , 18 , 24 month patient . - To establish molecular response rate 3 , 6 , 9 , 12 , 18 , 24 month patient . - To establish safety drug patient . - To correlate pharmacokinetic data response rate toxicity . - To correlate Bcr-Abl result use GeneXpert Bcr-Abl result use international standardized quantitative PCR . - To estimate prevalence Bcr-Abl mutation prior treatment . OUTLINE : This multicenter study . Patients receive oral nilotinib twice daily day 1-28 . Treatment repeat every 28 day 24 course absence disease progression unacceptable toxicity . Peripheral blood bone marrow sample collect periodically mutation analysis , Bcr-Abl analysis quantitative PCR , metaphase cytogenetics , pharmacokinetic analysis . After completion study therapy , patient follow every 3 month 2 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Cytogenetically confirm chronic myelogenous leukemia ( CML ) standard conventional cytogenetic analysis bone marrow* Newly diagnose disease ( within past 6 month ) NOTE : *FISH use In chronic phase , define follow : Less 15 % blast peripheral blood bone marrow Less 30 % blast plus promyelocytes peripheral blood bone marrow Less 20 % basophils peripheral blood Platelet count ≥ 100,000/mm^3 No evidence extramedullary leukemic involvement , except hepatosplenomegaly Philadelphia chromosomepositive disease demonstrate ( 9 ; 22 ) translocation ( presence BcrAbl ) A review ≥ 20 metaphase require No previously document T315I mutation PATIENT CHARACTERISTICS : ECOG performance status 02 Total bilirubin &lt; 1.5 time upper limit normal ( ULN ) AST ALT &lt; 2.5 time ULN Estimated glomerular filtration rate ≥ 30 mL/min Serum amylase lipase ≤ 1.5 time ULN Alkaline phosphatase ≤ 2.5 time ULN ( unless relate CML ) Potassium ≥ low limit normal ( LLN ) Magnesium ≥ LLN Phosphorous ≥ LLN Total calcium ≥ LLN ( correct serum albumin ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No impaired cardiac function include , limited , follow : LVEF &lt; 45 % &lt; LLN ECHO Inability determine QT interval ECG Complete leave bundle branch block Congenital long QT syndrome know family history long QT syndrome History presence clinically significant ventricular atrial tachyarrhythmias Clinically significant rest bradycardia ( &lt; 50 beats/min ) QTc &gt; 450 msec average 3 serial baseline ECGs ( use QTcF formula ) Clinically document myocardial infraction within past 12 month Unstable angina within past 12 month Other clinically significant heart disease ( e.g. , congestive heart failure uncontrolled hypertension ) No severe uncontrolled medical condition ( e.g. , uncontrolled diabetes active uncontrolled infection ) No history significant congenital acquire bleed disorder unrelated CML No history noncompliance medical regimens No primary malignancy unless neither currently clinically significant require active intervention No impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption study drug ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , small bowel resection , gastric bypass surgery ) No acute pancreatitis within past year No history chronic pancreatitis No acute chronic liver , pancreatic , severe renal disease consider unrelated CML PRIOR CONCURRENT THERAPY : No prior therapy CML hydroxyurea and/or anagrelide Prior imatinib mesylate allow provide administer ≤ 14 day More 30 day since prior concurrent investigational agent More 4 week since prior major surgery recover No concurrent anticancer agent , include chemotherapy biologic agents No concurrent strong CYP3A4 inhibitor ( e.g. , erythromycin , ketoconazole , itraconazole , voriconazole , clarithromycin , telithromycin , ritonavir , mibefradil ) No concurrent strong CYP3A4 inducer ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , St. John 's wort ) No concurrent medication potential prolong QT interval No concurrent grapefruit , star fruit , Seville oranges , derivative</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>chronic myelogenous leukemia , BCR-ABL1 positive</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
</DOC>